Form 4: Guardant Health Co-CEO Helmy Eltoukhy Reports Routine RSU Vesting and Tax-Related Share Dispositions

Guardant Health, Inc. Co-Chief Executive Officer and Director Helmy Eltoukhy reported the vesting of restricted stock units and subsequent tax-related share dispositions in late June and early July 2025.

Summary

• Helmy Eltoukhy, Co-Chief Executive Officer and Director of Guardant Health, Inc. (GH), reported changes in his beneficial ownership of common stock.
• On June 30, 2025, Eltoukhy acquired 4,815 shares of common stock at a price of $0 through the vesting of restricted stock units.
• Immediately following this acquisition on June 30, 2025, 2,441 shares were disposed of at a price of $52.04 to cover tax withholding obligations related to the RSU vesting.
• On July 1, 2025, an additional 23,997 shares of common stock were acquired at a price of $0 due to the vesting of another restricted stock unit award.
• Concurrently on July 1, 2025, 12,162 shares were disposed of at a price of $50.71 to satisfy tax withholding obligations for the RSU vesting.
• The 4,815 shares acquired on June 30, 2025, are part of an RSU award granted on March 12, 2025, vesting in four equal quarterly installments.
• The 23,997 shares acquired on July 1, 2025, are from an RSU award that initially vested 1/3 on January 1, 2025, with the remainder vesting quarterly over 24 months.
• Following these transactions, Helmy Eltoukhy's direct beneficial ownership of common stock stands at 2,423,499 shares.
• His beneficial ownership of derivative securities (Restricted Stock Units) is 9,629 units from one award and 143,983 units from another award.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are share dispositions, they are for tax purposes related to RSU vesting, which is a positive sign of executive compensation and retention. The transactions are routine and expected.

Positives

• The vesting of restricted stock units indicates the continued compensation and retention of a key executive, aligning management's interests with shareholders.
• The transactions are routine and pre-scheduled, reflecting standard compensation practices rather than discretionary sales.

Negatives

• A portion of the vested shares was sold to cover tax obligations, which reduces the executive's direct shareholding, although this is a common practice.

Future Outlook

Future vesting events for Helmy Eltoukhy's restricted stock units are scheduled for September 30, 2025, and December 31, 2025, for one award, and quarterly for the remaining twenty-four months for another award.

Industry Context

This Form 4 filing reflects routine insider compensation activities common across publicly traded companies, particularly in the biotechnology and healthcare sectors where equity-based compensation like Restricted Stock Units (RSUs) is a standard practice to attract and retain executive talent.

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation and do not indicate a significant change in company strategy or financial health. The tax-related sales are a common occurrence and typically have minimal impact on share price.

Next Steps

• Future vesting of restricted stock units on September 30, 2025, and December 31, 2025, for one award.
• Continued quarterly vesting for the remaining twenty-four months for another restricted stock unit award.

Key Dates

Keywords

Guardant Health, GH, Helmy Eltoukhy, Form 4, insider transaction, restricted stock units, RSU vesting, tax withholding, beneficial ownership, executive compensation